IVERIC bio

IVERIC bio is a biopharmaceutical company focusing on the development of therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company's therapeutics portfolio consists of Zimura? (avacincaptad pegol), which is a C5 complement inhibitor, and its program of High temperature requirement A serine peptidase 1 protein, or HtrA1, inhibitors.Co. has clinical trials ongoing evaluating Zimura for the treatment of geographic atrophy, which is a late-stage form of dry age-related macular degeneration; and autosomal recessive Stargardt disease, which is an orphan inherited retinal disease that also may result in loss of vision.
  • TickerISEE
  • ISINUS46583P1021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Initiating at OUTPERFORM: Talkin’ Bout Generation Bio

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

Initiating at OUTPERFORM: Talkin’ Bout Generation Bio

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

IVERIC BIO INCO. sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to IVERIC BIO INCO. (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date April 21, 2020, the closing price was USD 3.71 and its target price was estimated at USD 1.65.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch